Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 100

1.

Squamous Cell Transformation of Primary Lung Adenocarcinoma in a Patient With EML4-ALK Fusion Variant 5 Refractory to ALK Inhibitors.

Gong J, Gregg JP, Ma W, Yoneda K, Moore EH, Daly ME, Zhang Y, Williams MJ, Li T.

J Natl Compr Canc Netw. 2019 Apr 1;17(4):297-301. doi: 10.6004/jnccn.2019.7291.

PMID:
30959466
2.

GCC2-ALK as a targetable fusion in lung adenocarcinoma and its enduring clinical responses to ALK inhibitors.

Jiang J, Wu X, Tong X, Wei W, Chen A, Wang X, Shao YW, Huang J.

Lung Cancer. 2018 Jan;115:5-11. doi: 10.1016/j.lungcan.2017.10.011. Epub 2017 Oct 27.

PMID:
29290262
3.

Dual occurrence of ALK G1202R solvent front mutation and small cell lung cancer transformation as resistance mechanisms to second generation ALK inhibitors without prior exposure to crizotinib. Pitfall of solely relying on liquid re-biopsy?

Ou SI, Lee TK, Young L, Fernandez-Rocha MY, Pavlick D, Schrock AB, Zhu VW, Milliken J, Ali SM, Gitlitz BJ.

Lung Cancer. 2017 Apr;106:110-114. doi: 10.1016/j.lungcan.2017.02.005. Epub 2017 Feb 9.

4.

A new human lung adenocarcinoma cell line harboring the EML4-ALK fusion gene.

Isozaki H, Yasugi M, Takigawa N, Hotta K, Ichihara E, Taniguchi A, Toyooka S, Hashida S, Sendo T, Tanimoto M, Kiura K.

Jpn J Clin Oncol. 2014 Oct;44(10):963-8. doi: 10.1093/jjco/hyu110. Epub 2014 Aug 28.

PMID:
25170107
5.

Protocol Design for the Bench to Bed Trial in Alectinib-Refractory Non-Small-Cell Lung Cancer Patients Harboring the EML4-ALK Fusion Gene (ALRIGHT/OLCSG1405).

Isozaki H, Hotta K, Ichihara E, Takigawa N, Ohashi K, Kubo T, Ninomiya T, Ninomiya K, Oda N, Yoshioka H, Ichikawa H, Inoue M, Takata I, Shibayama T, Kuyama S, Sugimoto K, Harada D, Harita S, Sendo T, Tanimoto M, Kiura K.

Clin Lung Cancer. 2016 Nov;17(6):602-605. doi: 10.1016/j.cllc.2016.05.005. Epub 2016 Jun 2.

PMID:
27405684
6.

Differential protein stability and clinical responses of EML4-ALK fusion variants to various ALK inhibitors in advanced ALK-rearranged non-small cell lung cancer.

Woo CG, Seo S, Kim SW, Jang SJ, Park KS, Song JY, Lee B, Richards MW, Bayliss R, Lee DH, Choi J.

Ann Oncol. 2017 Apr 1;28(4):791-797. doi: 10.1093/annonc/mdw693.

7.

Updated Efficacy and Safety Data and Impact of the EML4-ALK Fusion Variant on the Efficacy of Alectinib in Untreated ALK-positive Advanced Non-small-cell Lung Cancer in the Global Phase III ALEX Study.

Camidge DR, Dziadziuszko R, Peters S, Mok T, Noe J, Nowicka M, Gadgeel SM, Cheema P, Pavlakis N, de Marinis F, Cho BC, Zhang L, Moro-Sibilot D, Liu T, Bordogna W, Balas B, Müller B, Shaw AT.

J Thorac Oncol. 2019 Mar 19. pii: S1556-0864(19)30210-2. doi: 10.1016/j.jtho.2019.03.007. [Epub ahead of print]

PMID:
30902613
8.
9.

P-glycoprotein Mediates Ceritinib Resistance in Anaplastic Lymphoma Kinase-rearranged Non-small Cell Lung Cancer.

Katayama R, Sakashita T, Yanagitani N, Ninomiya H, Horiike A, Friboulet L, Gainor JF, Motoi N, Dobashi A, Sakata S, Tambo Y, Kitazono S, Sato S, Koike S, John Iafrate A, Mino-Kenudson M, Ishikawa Y, Shaw AT, Engelman JA, Takeuchi K, Nishio M, Fujita N.

EBioMedicine. 2015 Dec 12;3:54-66. doi: 10.1016/j.ebiom.2015.12.009. eCollection 2016 Jan.

10.

Elucidation of Resistance Mechanisms to Second-Generation ALK Inhibitors Alectinib and Ceritinib in Non-Small Cell Lung Cancer Cells.

Dong X, Fernandez-Salas E, Li E, Wang S.

Neoplasia. 2016 Mar;18(3):162-71. doi: 10.1016/j.neo.2016.02.001.

11.

Carcinoma of Unknown Primary with EML4-ALK Fusion Response to ALK Inhibitors.

Zhao P, Peng L, Wu W, Zheng Y, Jiang W, Zhang H, Tong Z, Liu L, Ma R, Wang L, Yao M, Wang K, Fang W, Wu L.

Oncologist. 2019 Apr;24(4):449-454. doi: 10.1634/theoncologist.2018-0439. Epub 2019 Jan 24.

PMID:
30679319
12.

Next-generation sequencing facilitates detection of the classic E13-A20 EML4-ALK fusion in an ALK-FISH/IHC inconclusive biopsy of a stage IV lung cancer patient: a case report.

Volckmar AL, Endris V, Bozorgmehr F, Lier C, Porcel C, Kirchner M, Leichsenring J, Penzel R, Thomas M, Schirmacher P, Warth A, Stenzinger A.

Diagn Pathol. 2016 Nov 18;11(1):133.

13.

In vivo imaging models of bone and brain metastases and pleural carcinomatosis with a novel human EML4-ALK lung cancer cell line.

Nanjo S, Nakagawa T, Takeuchi S, Kita K, Fukuda K, Nakada M, Uehara H, Nishihara H, Hara E, Uramoto H, Tanaka F, Yano S.

Cancer Sci. 2015 Mar;106(3):244-52. doi: 10.1111/cas.12600. Epub 2015 Feb 17.

14.

I1171 missense mutation (particularly I1171N) is a common resistance mutation in ALK-positive NSCLC patients who have progressive disease while on alectinib and is sensitive to ceritinib.

Ou SH, Greenbowe J, Khan ZU, Azada MC, Ross JS, Stevens PJ, Ali SM, Miller VA, Gitlitz B.

Lung Cancer. 2015 May;88(2):231-4. doi: 10.1016/j.lungcan.2015.02.005. Epub 2015 Feb 12.

PMID:
25736571
15.

Use of capture-based next-generation sequencing to detect ALK fusion in plasma cell-free DNA of patients with non-small-cell lung cancer.

Cui S, Zhang W, Xiong L, Pan F, Niu Y, Chu T, Wang H, Zhao Y, Jiang L.

Oncotarget. 2017 Jan 10;8(2):2771-2780. doi: 10.18632/oncotarget.13741.

16.

ALK F1174V mutation confers sensitivity while ALK I1171 mutation confers resistance to alectinib. The importance of serial biopsy post progression.

Ou SH, Milliken JC, Azada MC, Miller VA, Ali SM, Klempner SJ.

Lung Cancer. 2016 Jan;91:70-2. doi: 10.1016/j.lungcan.2015.09.006. Epub 2015 Sep 12.

PMID:
26464158
17.

ALK Fusions in a Wide Variety of Tumor Types Respond to Anti-ALK Targeted Therapy.

Ross JS, Ali SM, Fasan O, Block J, Pal S, Elvin JA, Schrock AB, Suh J, Nozad S, Kim S, Jeong Lee H, Sheehan CE, Jones DM, Vergilio JA, Ramkissoon S, Severson E, Daniel S, Fabrizio D, Frampton G, Miller VA, Stephens PJ, Gay LM.

Oncologist. 2017 Dec;22(12):1444-1450. doi: 10.1634/theoncologist.2016-0488. Epub 2017 Oct 27.

18.

Clinical significance of EML4-ALK fusion gene and association with EGFR and KRAS gene mutations in 208 Chinese patients with non-small cell lung cancer.

Li Y, Li Y, Yang T, Wei S, Wang J, Wang M, Wang Y, Zhou Q, Liu H, Chen J.

PLoS One. 2013;8(1):e52093. doi: 10.1371/journal.pone.0052093. Epub 2013 Jan 14.

19.

Spotlight on ceritinib in the treatment of ALK+ NSCLC: design, development and place in therapy.

Santarpia M, Daffinà MG, D'Aveni A, Marabello G, Liguori A, Giovannetti E, Karachaliou N, Gonzalez Cao M, Rosell R, Altavilla G.

Drug Des Devel Ther. 2017 Jul 5;11:2047-2063. doi: 10.2147/DDDT.S113500. eCollection 2017. Review.

20.

Anaplastic lymphoma kinase (ALK) inhibitors in the treatment of ALK-driven lung cancers.

Roskoski R Jr.

Pharmacol Res. 2017 Mar;117:343-356. doi: 10.1016/j.phrs.2017.01.007. Epub 2017 Jan 8. Review.

PMID:
28077299

Supplemental Content

Support Center